肿瘤标志物血清miR-429、CEA、AFF3、CA199联合诊断胰腺癌的价值

摘要/Abstract

摘要： 目的探讨与分析肿瘤标志物血清miR-429、癌胚抗原（CEA）、AFF3、糖类抗原199（CA199）联合诊断胰腺癌的价值。方法选取2018年8月—2022年12月在内蒙古自治区精神卫生中心接受检验的105例胰腺癌患者作为胰腺癌组,同期选取在内蒙古自治区精神卫生中心接受检验的105例胰腺良性结节作为良性组。检测胰腺癌组与良性组的血清miR-429、CEA、AFF3、CA199水平,判断阳性率与诊断价值。结果胰腺癌组的血清CEA、AFF3、CA199含量显著高于良性组（P<0.05）,血清miR-429相对表达水平与良性组相比也显著增加（P<0.05）。胰腺癌组的血清miR-429、CEA、AFF3、CA199表达阳性率为74.29%、80.00%、84.76%、90.48%,显著高于良性组的4.76%、5.71%、3.81%、6.67%（P<0.05）。在胰腺癌210例患者中,Pearson相关分析显示血清miR-429、CEA、AFF3、CA199表达水平与组织学分化、临床分期、淋巴结转移等存在相关性（P<0.05）。肿瘤标志物血清miR-429、CEA、AFF3、CA199判断为胰腺癌104例,肿瘤标志物血清miR-429、CEA、AFF3、CA199鉴别诊断胰腺癌的敏感性与特异性分别为98.10%（103/105）、99.05%（104/105）,阳性预测值为99.04%（103/104）,阴性预测值为98.11%（104/106）。受试者操作特征（ROC）曲线分析显示肿瘤标志物血清miR-429、CEA、AFF3、CA199联合诊断胰腺癌的最大曲线下面积为0.920,Kappa检验分析联合诊断的一致性为0.874。结论胰腺癌多伴随有血清miR-429、CEA、AFF3、CA199的高表达,与患者的病理特征存在相关性,肿瘤标志物血清miR-429、CEA、AFF3、CA199联合诊断胰腺癌具有很高的敏感度与特异度。

关键词: 胰腺癌, miR-429, 癌胚抗原, AFF3, 糖类抗原199, 病理特征, 诊断价值

Abstract: Objective To explore and analysis the values of combined diagnosis of tumor markers serum miR-429, CEA, AFF3, CA199 in pancreatic cancer. Methods From August 2018 to December 2022, 105 cases of patients with pancreatic cancer diagnosed and treated in Inner Mongolia Autonomous Region Mental Health Center were selected as the pancreatic cancer group, and 105 cases of patients with benign pancreatic nodules diagnosed and treated in th same hospital were selected as the benign group at the same time. The levels of serum miR-429, CEA, AFF3, and CA199 in both groups were detected. And the positive rate was calculated and diagnostic values were evaluated. Results The levels of serum CEA, AFF3, CA199 in the pancreatic cancer group were significantly higher than those in the control group (P<0.05), and the relative expression level of serum miR-429 was also significantly higher than that in the control group (P<0.05). The positive rates of serum miR-429, CEA, AFF3, CA199 expression in pancreatic cancer group were 74.29%, 80.00%, 84.76%, 90.48%, significantly higher than 4.76%, 5.71%, 3.81%, 6.67% in the control group (P<0.05). In the 210 patients with pancreatic cancer, the expression levels of serum miR-429, CEA, AFF3 and CA199 were correlated with histological differentiation, clinical stage and lymph node metastasis (P<0.05). There were 104 cases of pancreatic cancer were diagnosed by tumor marker serum miR-429, CEA, AFF3 and CA199. The sensitivity and specificity of tumor marker serum miR-429, CEA, AFF3 and CA199 in differential diagnosis of pancreatic cancer were 98.10% (103/105) and 99.05% (104/105) respectively. The positive predictive value were 99.04% (103/104), and the negative predictive value were 98.11% (104/106). ROC analysis showed that the maximum area under the curve of serum miR-429, CEA, AFF3, CA199 combined diagnosis of pancreatic cancer was 0.920, and the consistency of Kappa test on the tumor markers combined diagnosis was 0.874. Conclusion High expression of serum miR-429, CEA, AFF3, CA199 is often associated with pancreatic cancer, which is related to the pathological characteristics of patients. The combination of serum miR-429, CEA, AFF3, CA199 has relatively high sensitivity and specificity in the diagnosis of pancreatic cancer.

Key words: pancreatic cancer, miR-429, carcinoembryonic antigen, AFF3, carbohydrate antigen 199, pathological characteristics, diagnostic value

中图分类号:

R735.9

刘永生. 肿瘤标志物血清miR-429、CEA、AFF3、CA199联合诊断胰腺癌的价值[J]. 中华养生保健, 2024, 42(8): 163-166.

LIU Yong-sheng. The Value of Tumor Marker Serum miR-429, CEA, AFF3, CA199 in the Diagnosis of Pancreatic Cancer[J]. ZHONGHUA YANGSHENG BAOJIAN, 2024, 42(8): 163-166.

参考文献

[1] 王海宇,谢方瑜,吕梅,等.联合检测血清miR-1290和CA19-9对胰腺癌的诊断价值[J].医学研究杂志,2023,52(1):115-119,167.
[2] 中华医学会外科学分会胰腺外科学组. 胰腺癌诊治指南(2014版)[J]. 中华消化外科杂志,2014,13(11):831-837.
[3] 李文文,孙鹏鹏,戚浩田,等.1例体检者CA19-9水平假性异常升高的处理及分析[J].检验医学与临床,2023,20(4):574-576.
[4] 师兆达,王飞,靳君华,等.miR-429及AFF3在胰腺癌中的潜在应用[J].医学研究杂志,2023,52(1):15-17,22.
[5] 武晓慧,杨帆,郭新茹,等.奥利司他联合EZH2抑制剂GSK126对胰腺癌细胞脂质代谢重编程的影响[J].吉林大学学报(医学版),2023,49(1):55-66.
[6] 李永元,孙广玉,崔玉,等.骨髓间充质干细胞分泌的外泌体诱导肿瘤相关巨噬细胞极化调控胰腺癌细胞实验研究[J].中华实验外科杂志,2023,40(1):18-21.
[7] 高博文,罗宇明,孔瑶,等.circRNA-CHD2通过miR-30e-3p/MDM2/TP53轴促进胰腺癌侵袭转移[J].中华普通外科学文献(电子版),2022,16(1):14-19.
[8] 陈小芳,韩晓锐.lncRNA NR2F2在胰腺癌组织中的表达及其与患者预后的关系[J].浙江医学,2022,44(12):1313-1316.
[9] 钱道海,奚士航,王冠男,等.基于Hsp90α的胰腺癌化疗耐药预警机制构建及其临床转化[J].皖南医学院学报,2022,41(2):124-127.
[10] 郭马娣,赵娟,黄小义.以外泌体为基础的液体活检在胰腺癌诊断中的研究进展[J].肿瘤防治研究,2022,49(3):240-245.
[11] 何傲月,赵旭,郝洁,等.硒蛋白硫氧还蛋白还原酶3对肿瘤患者生存预后的影响[J].中国医学科学院学报,2022,44(6):970-979.
[12] 党啟华,李艳茹.紧密连接蛋白4在胰腺癌中预后价值及机制的生物信息学分析[J].国际老年医学杂志,2022,43(6):643-648.
[13] 臧龙军,陈东杰,高文哲,等.长链非编码 RNA SOX21-AS1调控 miR-31-5p/MMP-16轴对胰腺癌细胞活性与增殖的影响[J].中国普通外科杂志,2022,31(3):329-339.
[14] 褚翔宇,杨尹默,田孝东.外泌体长链非编码RNA在胰腺癌诊断中的应用现状与展望[J].中华实验外科杂志,2022,39(12):2513-2516.
[15] 邵建平,蔡雪军,井树森,等.骨髓间充质干细胞分泌的外泌体调控肿瘤相关巨噬细胞治疗胰腺癌的实验研究[J].中华肝胆外科杂志,2022,28(12):931-935.
[16] 李源,任帅,曹营营,等.早期胰腺癌患者血清外泌体差异miRNA筛选及hsa-let-7f-5p的诊断价值[J].中华胰腺病杂志,2022,22(6):432-438.
[17] 杨冬梅,王睿,潘怡,等.长链非编码RNA在胰腺癌中的研究进展[J].药物生物技术,2022,29(3):305-309.
[18] 涂东,于杰,蔡文科,等.胰腺癌CAR-T免疫治疗研究进展[J].解放军医学杂志,2022,47(4):419-426.
[19] 王健力,俞泽元,陈志涛,等.TRIM21与胰腺癌临床病理特征及免疫浸润的相关性分析[J].重庆医科大学学报,2022,47(2):201-208.
[20] YU J.液体活检在消化道肿瘤诊治中的应用进展[J].中华结直肠疾病电子杂志,2022,11(2):104-107.